Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Nov
07
Today In Oncology
Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds
OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL
American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health
Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo